Todistustutkimus SAR445088:lle kroonisessa tulehduksellisessa demyelinisoivassa polyneuropatiassa (CIDP)
Vaihe 2, monikeskus, avoin, ei-satunnaistettu, konseptitutkimus, jossa arvioidaan SAR445088:n tehoa, turvallisuutta ja siedettävyyttä aikuisilla, joilla on krooninen tulehduksellinen demyelinisoiva polyneuropatia (CIDP)
Primary Objectives:
- Part A: Efficacy of SAR445088 across three subpopulations of CIDP patients: standard of care (SOC)-Treated, SOC-Refractory and SOC-Naive
- Part B:Long-term safety and tolerability of SAR445088 in CIDP
Secondary Objectives:
-
Part A:
- Safety and tolerability of SAR445088 in CIDP
- Immunogenicity of SAR445088
- Efficacy of SAR445088 with overlapping SOC (SOC-Treated group)
-
Part B:
- Durability of efficacy during long-term treatment with SAR445088 in CIDP
- Long-term immunogenicity of SAR445088 in CIDP
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
The duration of the study for a participant will include:
Part A Screening period: up to 6 weeks. Treatment period: once successfully screened, enrolled participants will receive study intervention for 24 weeks.
Safety follow-up visit: participants who do not enroll (rollover) into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24, ie, approximately at Week 46.
Part B Treatment period (extension): for all groups, this period will consist of 52 weeks of treatment with SAR445088 (Weeks 24 to 76; Part A and B total treatment period of 76 weeks).
Safety follow-up visit: participants who do not enroll (rollover) into Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (Week 98).
Part C Treatment period: participants who complete Part B will be reassessed for continuing eligibility, defined as having successfully completed Part B (received IMP until the Week 76 visit and have responded to SAR445088 based on Investigator's medical judgement), with no new safety concerns. Eligible participants will be given the option of rolling into Part C, where they will continue receiving SAR445088 until end of study.
End of study has been defined as the last safety follow-up visit for the last patient which occurs 22 weeks after last dose.
In addition, there is a follow-up call 56 weeks ±14 days after last dose to confirm negative result of urine pregnancy test for women of childbearing potential who are participating in the study, or to query male participants regarding pregnancy of partners who are women of childbearing potential.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 2
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Amsterdam, Alankomaat, 1105 AZ
- Investigational Site Number : 5280001
-
-
-
-
-
Valencia, Espanja, 46026
- Investigational Site Number : 7240003
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Espanja, 08035
- Investigational Site Number : 7240002
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Espanja, 08041
- Investigational Site Number : 7240001
-
-
-
-
Genova
-
Genoa, Genova, Italia, 16132
- Investigational Site Number : 3800003
-
-
Milano
-
Milan, Milano, Italia, 20132
- Investigational Site Number : 3800001
-
Rozzano, Milano, Italia, 20089
- Investigational Site Number : 3800005
-
-
Roma
-
Rome, Roma, Italia, 00168
- Investigational Site Number : 3800002
-
-
-
-
Quebec
-
Gatineau, Quebec, Kanada, J8Y 1W2
- Investigational Site Number : 1240001
-
Québec, Quebec, Kanada, G1J 1Z4
- Investigational Site Number : 1240002
-
-
-
-
-
Fuzhou, Kiina, 350001
- Investigational Site Number : 1560002
-
Shanghai, Kiina, 200040
- Investigational Site Number : 1560001
-
Wuhan, Kiina, 430030
- Investigational Site Number : 1560004
-
-
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Puola, 20-954
- Investigational Site Number : 6160001
-
-
-
-
-
Bordeaux, Ranska, 33076
- Investigational Site Number : 2500003
-
Le Kremlin-Bicêtre, Ranska, 94270
- Investigational Site Number : 2500005
-
Marseille, Ranska, 13885
- Investigational Site Number : 2500001
-
Nice, Ranska, 06001
- Investigational Site Number : 2500002
-
-
-
-
-
Düsseldorf, Saksa, 40225
- Investigational Site Number : 2760001
-
Göttingen, Saksa, 37075
- Investigational Site Number : 2760002
-
Tübingen, Saksa, 72076
- Investigational Site Number : 2760004
-
-
-
-
-
Belgrade, Serbia, 11000
- Investigational Site Number : 6880001
-
Niš, Serbia, 18000
- Investigational Site Number : 6880003
-
-
-
-
California
-
Los Angeles, California, Yhdysvallat, 90033
- USC Norris Comprehensive Cancer Center- Site Number : 8400004
-
Orange, California, Yhdysvallat, 92868
- University of California Irvine - Manchester Pavilion- Site Number : 8400002
-
-
Kansas
-
Fairway, Kansas, Yhdysvallat, 66205
- University of Kansas Clinical Research Center- Site Number : 8400003
-
-
Minnesota
-
Minneapolis, Minnesota, Yhdysvallat, 55455
- M Health Fairview University of Minnesota Medical Center - East Bank- Site Number : 8400006
-
-
New York
-
New York, New York, Yhdysvallat, 10032
- Columbia University Irving Medical Center- Site Number : 8400005
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Adults ≥18 years of age at the time of signing the informed consent.
- Documented definite or probable diagnosis of CIDP (typical CIDP, pure motor CIDP, or Lewis-Sumner Syndrome) according to the European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) Task Force first revision.
- Belonging to one of the following three groups: standard-of-care (SOC)-Treated, SOC-Refractory or SOC-Naive, as defined below.
- SOC-Treated (all criteria a-c must be met): a) Documented evidence of objective response to SOC, with clinically meaningful improvement. Clinically meaningful improvement is defined as one of the following: ≥1-point decrease in adjusted INCAT score, ≥4 points increase in RODS total score, ≥3 points increase in MRC Sum score, ≥8 kilopascal improvement in mean grip strength (one hand), or an equivalent improvement based on information documented in medical records and per the PI's judgement. b) Must be on stable SOC therapy, defined as no change greater than 10% in frequency or dose of immunoglobulin therapy or corticosteroids within 8 weeks prior to screening, remaining at stable SOC therapy until the time of first SAR445088 dosing. c) Evidence of clinically meaningful deterioration on interruption or dose reduction of SOC therapy within 24 months prior to screening, determined by clinical examination or medical records. Clinically meaningful deterioration is defined as one of the following: ≥1-point increase in adjusted INCAT score, decrease in RODS total score ≥4 points, decrease in MRC Sum score ≥3, mean grip strength worsening of ≥8 kilopascals (one hand), or an equivalent deterioration based on information from medical records and at the PI's judgement.
- SOC-Refractory (all criteria a-d must be met): a) Evidence of failure or inadequate response to SOC defined as no clinically meaningful improvement and persistent INCAT score ≥2 after treatment for a minimum of 12 weeks on SOC prior to screening. A clinically meaningful improvement is defined as one of the following: ≥1-point decrease in adjusted INCAT score, increase in RODS total score ≥4 points, increase in MRC Sum score ≥3, mean grip strength improvement of ≥8 kilopascals (one hand), or equivalent improvement based on information from medical records and at the PI's judgement.
Or
- Unable to receive or continue treatment with immunoglobulins or corticosteroids due to side effects.
- b) Patient has not received immunoglobulins (IVIg or SCIg) within 12 weeks prior to screening. c) Certain immunosuppressant drugs are allowed in this group if taken for ≥6 months and at a stable dose for ≥3 months prior to screening: azathioprine, methotrexate, mycophenolate mofetil and cyclosporine. Oral corticosteroids are allowed if on a stable dose of <20 mg/day of prednisone (or equivalent dose for other oral corticosteroids) for ≥3 months prior to screening. d) INCAT score: 2-9 (a score of 2 should be exclusively from leg disability component of INCAT).
- SOC-Naive (all criteria a-c must be met): a) Participants without previous treatment for CIDP or participants who received immunoglobulins (IVIg or SCIg) or corticosteroids but were stopped for reasons other than lack of response or side effects. b) Not treated with immunoglobulins (IVIg or SCIg) or corticosteroids for at least 6 months prior to screening. c) INCAT score: 2-9 (a score of 2 should be exclusively from leg disability component of INCAT.
- Documented vaccinations against encapsulated bacterial pathogens given within 5 years of enrollment or initiated a minimum of 14 days prior to first dose
- A female participant must use a double contraception method including a highly effective method of birth control from inclusion and up to 52 weeks plus 30 days after the last study dose and agree not to donate eggs, ova or oocytes during this period.
- A female participant must have a negative highly sensitive pregnancy test (urine or serum) as required by local regulations within 24 hours before the first dose of study intervention.
- Male participants, whose partners are of childbearing potential must accept to use, during sexual intercourse, a double contraceptive method according to the following: condom plus an additional highly effective contraception
- Male participants must have agreed not to donate sperm during the intervention and up to 52 weeks after the last dose.
- Capable of giving signed informed consent
Exclusion Criteria:
- Polyneuropathy of other causes, including but not limited to hereditary demyelinating neuropathies, neuropathies secondary to infection or systemic disease, diabetic neuropathy, drug- or toxin-induced neuropathies, multifocal motor neuropathy, polyneuropathy related to IgM monoclonal gammopathy, POEMS syndrome, lumbosacral radiculoplexus neuropathy, pure sensory CIDP and acquired demyelinating symmetric (DADS) neuropathy (also known as distal CIDP).
- Any other neurological or systemic disease that can cause symptoms and signs interfering with treatment or outcome assessments.
- Poorly controlled diabetes (HbA1c >7%).
- Serious infections requiring hospitalization within 30 days prior to screening and any active infection requiring treatment during screening.
- Clinical diagnosis of SLE.
- Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study. Specifically, history of any hypersensitivity reaction to SAR445088 or its components or of a severe allergic or anaphylactic reaction to any humanized or murine monoclonal antibody.
- Participants with a history of suicidality in the six months prior to screening or currently at risk of committing suicide.
- Presence of conditions (medical history or laboratory assessments) that may predispose the participant to excessive bleeding or increased risk of infection.
- Evidence of CIDP relapse within 6 weeks after receiving a vaccination.
- Recent or planned major surgery that could confound the results of the trial or put the participant at undue risk.
- Treatment with plasma exchange within 12 weeks prior to screening.
- Prior treatment with rituximab or ocrelizumab in the 6 months prior to SAR445088 dosing or until return of B-cell counts to normal levels, whichever is longer.
- Immunosuppressive/chemotherapeutic medications such as azathioprine, methotrexate, cyclophosphamide, cyclosporine, mycophenolate mofetil, tacrolimus, interferon, TNF-alpha inhibitor: within 6 months prior to dosing (except for some cases as indicated in the SOC-Refractory group).
- Treatment (any time) with highly immunosuppressive/chemotherapeutic medications with sustained effects, eg, mitoxantrone, alemtuzumab, cladribine.
- Treatment (any time) with total lymphoid irradiation or bone marrow transplantation.
- Use of any specific complement system inhibitor (eg, eculizumab) within 12 weeks or 5 times the half-life of the product, whichever is longer, prior to screening.
- Pregnant (defined as positive β-HCG blood test) or lactating females.
- Positive result on any of the following tests: hepatitis B surface (HBsAg) antigen, anti-hepatitis B core antibodies (anti-HBc Ab)-unless anti-hepatitis B surface antibodies (anti-HBs Ab) are also positive , indicating natural immunity-, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 antibodies).
- Evidence of IgG4 autoantibodies against paranodal proteins (NF155 and CNTN1).
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: SOC-Refractory Initial Dose
Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately (~)at Week 46). Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they will not continue in Part C. Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose. |
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV) Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC) |
|
Kokeellinen: SOC-Refractory Low Dose
Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46). Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility and will be given the option to roll into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (approximately week 98) if they do not continue in Part C. Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose. |
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV) Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC) |
|
Kokeellinen: SOC-Treated Initial Dose
Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects of SOC therapy; Weeks 13-24: SAR445088 given. Participants who do not enroll into Part B will attend final safety follow-up visit at 22 weeks after Week 24 (~Week 46). Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (~week 98) if they do not continue in Part C. Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit at 22 weeks after the last SAR445088 dose. |
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV) Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC) |
|
Kokeellinen: SOC-Naive
Part A: Eligible participants will receive SAR445088 for 24 weeks. Participants who do not enroll into Part B will be asked to attend a final safety follow-up visit that will take place 22 weeks after Week 24 (approximately at Week 46). Part B: Participants who successfully complete Part A, will be reassessed for continuing eligibility and will be given the option of rolling into Part B, where they will continue receiving SAR445088 for an additional 52 weeks. At the end of the Part B treatment period, participants will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose (approximately week 98) if they do not continue in Part C. Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until the end of study. Participants who discontinue at any time during Part C will be asked to attend a safety follow-up visit that will take place 22 weeks after last SAR445088 dose. |
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV) Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC) |
|
Kokeellinen: SOC-Treated Low Dose
Part A: Eligible participants will receive SAR445088 for 24 weeks. Weeks 1-12 (overlap period): Participants will be given SAR445088 with superimposing effects SOC therapy; Weeks 13-24: SAR445088. Participants who do not enroll into Part B will attend a final safety follow-up visit that will take place 22 weeks after Week 24 (~Week 46). Part B: Participants who successfully complete Part A, will be reassessed for continued eligibility, will be given the option of rolling into Part B, and continue receiving SAR445088 for 52 weeks. At the end of the Part B treatment period, participants will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose (~week 98) if they do not continue in Part C. Part C: Participants from Part B who enter Part C will continue receiving SAR445088 until end of study. Participants who discontinue at any time in Part C will attend a safety follow-up visit that will take place 22 weeks after the last SAR445088 dose. |
Pharmaceutical form: Solution for Injection Route of Administration: Intravenous (IV) Pharmaceutical form: Solution for Injection Route of Administration: Subcutaneous (SC) |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part A: Standard of Care-Treated Only: Percentage of Participants With Relapse After Withdrawal of Standard of Care During the Riliprubart Treatment Period
Aikaikkuna: From Day 1 up to Week 24
|
The relapse was defined as >=1-point increase in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place. |
From Day 1 up to Week 24
|
|
Part A: Standard of Care-Refractory Only: Percentage of Participants With Response During the Riliprubart Treatment Period
Aikaikkuna: From Day 1 up to Week 24
|
The response was defined as >=1 point decrease in adjusted INCAT disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place. |
From Day 1 up to Week 24
|
|
Part A: Standard of Care-Naïve Only: Percentage of Participants With Response During the Riliprubart Treatment Period
Aikaikkuna: From Day 1 up to Week 24
|
The response was defined as >=1 point decrease in adjusted INCAT disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place. |
From Day 1 up to Week 24
|
|
Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
Aikaikkuna: From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks
|
An adverse event (AE) is any untoward medical occurrence in a participant or clinical study participant temporally associated with use of study treatment, whether or not considered related to study treatment. An SAE is defined as any AE that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is a suspected transmission of any infectious agent via an authorized medicinal product or other situations where medical or scientific judgment exercised by Investigator. The Investigator assessed severity for each AE and SAE using NCI CTCAE Version 5.0, that is, Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death). TEAEs are defined as AEs that developed, worsened or became serious during treatment-emergent (TE) period (Part A: 24 weeks and Part B: 52 weeks). |
From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Part A: Number of Participants With Treatment-Emergent Adverse Events and Treatment-Emergent Serious Adverse Events
Aikaikkuna: From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks
|
An AE is any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE is defined as any AE that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is a suspected transmission of any infectious agent via an authorized medicinal product or other situations where medical or scientific judgment exercised by the Investigator. The Investigator assessed severity for each AE and SAE using NCI CTCAE Version 5.0, that is, Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death). The TEAEs are defined as AEs that developed, worsened or became serious during TE period (Part A: 24 weeks). |
From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks
|
|
Part A: Number of Participants With Anti-Drug Antibodies (ADA) for Riliprubart During the Treatment and Follow-up Period
Aikaikkuna: From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks
|
Treatment-induced ADAs were defined as participants with ADAs that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADAs were defined as participants with pre-existing ADAs that were boosted during the TE period to a significantly higher titer than the baseline. A 2-fold serial dilution schema was used during titration, so at least a 4-fold increase was considered as significant. |
From the first dose of study drug administration (Day 1) until end of the Part A follow-up period, approximately 46 weeks
|
|
Part A (Standard of Care-Treated: Riliprubart Initial Dose Only): Percentage of Participants With Improvement During the Overlap Treatment Period
Aikaikkuna: From Day 1 up to Week 12
|
Improvement was defined as a >=1 point decrease in adjusted INCAT disability score. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place. |
From Day 1 up to Week 12
|
|
Part B (Standard of Care-Treated: Riliprubart Initial Dose Only): Percentage of Participants With Relapse-Free During the Treatment Extension Period
Aikaikkuna: From Week 24 through Week 76, that is, Weeks 36, 48, 60 and 76
|
The relapse-free was defined as no increase in adjusted INCAT disability score >=2 points. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place. |
From Week 24 through Week 76, that is, Weeks 36, 48, 60 and 76
|
|
Part B (Excluding Standard of Care-Treated: Riliprubart Low Dose): Percentage of Participants With Sustained Response During the Treatment Extension Period
Aikaikkuna: From Week 24 through Week 76
|
The sustained response was defined as no increase in adjusted INCAT disability score >=2 points. Adjusted INCAT disability score was identical to the INCAT disability score, except for the exclusion of changes from baseline in arm disability from 0 (normal) to 1 (minor symptoms or signs in one or both arms but not affecting any of the functions listed in the scale) or from 1 to 0. The percentages are rounded off to the tenth decimal place. |
From Week 24 through Week 76
|
|
Parts A and B: Number of Participants With Anti-Drug Antibodies for Riliprubart During the Entire Treatment and Follow-up Period
Aikaikkuna: From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks
|
Treatment-induced ADAs were defined as participants with ADAs that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADAs were defined as participants with pre-existing ADAs that were boosted during the TE period to a significantly higher titer than the baseline. A 2-fold serial dilution schema was used during titration, so at least a 4-fold increase was considered as significant. |
From the first dose of study drug administration (Day 1) until end of the Part B follow-up period, approximately 98 weeks
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Opintojohtaja: Clinical Sciences & Operations, Sanofi
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Todellinen)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Hermoston sairaudet
- Patologiset prosessit
- Neuromuskulaariset sairaudet
- Krooninen sairaus
- Sairauden ominaisuudet
- Autoimmuunisairaudet
- Immuunijärjestelmän sairaudet
- Ääreishermoston sairaudet
- Hermoston autoimmuunisairaudet
- Demyelinisoivat sairaudet
- Polyneuropatiat
- Polyradikuloneuropatia
- Patologiset tilat, merkit ja oireet
- Polyradikuloneuropatia, krooninen tulehduksellinen demyelinisaatio
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- PDY16744
- 2020-004006-54 (EudraCT-numero)
- U1111-1246-7023 (Rekisterin tunniste: ICTRP)
- 2024-512345-16-00 (Rekisterin tunniste: CTIS)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .